A controlled clinical trial of treatment with ALG in established rejection of renal allografts.
A controlled clinical investigation of the effect of equine anti-human-lymphocyte globulin (ALG) on established rejection after transplantation has been carried out in a group of 31 patients. Compared with a control group, the treated group showed a significantly positive effect of ALG in the form of a faster reversal of rejection episodes (p less than 0.05). Leucocytes, lymphocytes, erythrocytes, thrombocytes and immunoglobulins were unaffected by the treatment, but there were signs of a complement-consuming process and an influence on blast transformation tests. No rise in antibody titre against equine globulin was seen.
D000906:Antibodies; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003165:Complement System Proteins; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000601:surgery; D006084:Graft Rejection; D006801:Humans; D006974:Hypertension, Malignant / Q000601:surgery; D007136:Immunoglobulins; D052177:Kidney Diseases, Cystic / Q000601:surgery; D007678:Kidney Glomerulus / Q000276:immunology; D016030:Kidney Transplantation; D008213:Lymphocyte Activation; D011704:Pyelonephritis / Q000601:surgery; D014184:Transplantation, Homologous
D000906:Antibodies; D000961:Antilymphocyte Serum; D007136:Immunoglobulins; D003165:Complement System Proteins